

2 June 2021 07:00 BST

### Publication of Final Terms for €800m bond offering

The Final Terms, dated 1 June 2021, relating to the issue by AstraZeneca PLC of €800,000,000 of fixed rate notes with a coupon of 0.375%, maturing on 3 June 2029 (the “Notes”) are available for viewing.

The Notes will be issued under the \$10,000,000,000 EMTN programme of AstraZeneca PLC and AstraZeneca Finance LLC. The Final Terms must be read in conjunction with the Base Prospectus dated 24 May 2021.

To view the Final Terms for the Notes, please paste the following URL into the address bar of your browser:

[http://www.rns-pdf.londonstockexchange.com/rns/5008A\\_1-2021-6-1.pdf](http://www.rns-pdf.londonstockexchange.com/rns/5008A_1-2021-6-1.pdf)

A copy of the above Final Terms will shortly be available for inspection at:

<https://data.fca.org.uk/#/nsm/nationalstoragemechanism>

### AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries, and its innovative medicines are used by millions of patients worldwide. Please visit [astrazeneca.com](http://astrazeneca.com) and follow the Company on Twitter [@AstraZeneca](https://twitter.com/AstraZeneca).

### Contacts

For details on how to contact the Investor Relations Team, please click [here](#). For Media contacts, click [here](#).

**Adrian Kemp**  
Company Secretary  
AstraZeneca PLC